Skip to main content
Caplight Logo









Hemab Therapeutics

Hemab Therapeutics

Public
Copenhagen, Capital Region of DenmarkBiotechhttps://www.hemab.com/

Hemab Therapeutics is now publicly traded

The data on this page reflects Hemab Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Went Public

May 1, 2026

Last Round

Series C

Oct 27, 2025

Total Funding Raised

$853.66M

Company Overview

Hemab Therapeutics is a biotechnology company that develops prophylactic therapeutics aimed at treating bleeding and thrombosis disorders by enhancing the body's natural clotting mechanisms to prevent life-threatening complications.

Sector

Biotech

Verticals

Digital Health, HealthTech, Life Sciences

AI Layer

Non-AI

Keywords

biotechnologymonoclonal antibodybleeding disordersrare diseaseclinical-stage biotechbispecific antibodyGlanzmann Thrombastheniablood coagulationprophylactic therapeuticsclinical trialsdrug developmentorphan drugbiopharmahematologypipeline assets

Hemab Therapeutics Comparables

Compare Hemab Therapeutics with similar companies based on industry and business-model similarity.

Hemab Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Eli Lilly and Company
77%
Incyte Corporation
76%
Novo Nordisk
72%

Hemab Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
IPOMay 1, 2026
Series COct 27, 2025
Series COct 27, 2023
Series BFeb 16, 2023
Series AJul 22, 2021
Seed
Dec 14, 2020

Key People

Founding team and executive leadership

Benny Sorensen

Chief Executive Officer

Executive Team

Mads Behrndt

Chief Financial Officer

Executive Team

Hemab Therapeutics Investors

Notable investors and investment history

Hemab Therapeutics investors
InvestorRounds
JefferiesIPO
Access IndustriesSeries B
Evercore ISIIPO
Maj Invest Equity A/SSeries B, Series C
RA Capital ManagementSeries C, Series B, Series A
Avoro VenturesSeries C, Series B
Avoro CapitalSeries B

Recent news

Latest coverage and updates

  • is_developingSep 24, 2026

    Hemab is developing franchise of innovative therapeutics.

  • hiresSep 24, 2026

    Hemab hired Keli as Board of Directors on Sep 24th '26.

  • hiresSep 24, 2026

    Hemab hired Keli Walbert as Board of Directors on Sep 24th '26.

  • launchesJul 12, 2026

    Hemab ApS launched HMB-003 program at International Society on Thrombosis and Haemostasis, ISTH, 2026 Congress on Jul 12th '26.

  • attends_eventJul 12, 2026

    Hemab ApS attended event International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress on Jul 12th '26.

Hemab Therapeutics Filings

Explore SEC and related filing metadata, where available.

Hemab Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

HeadquartersCopenhagen, Capital Region of Denmark
Employee Range86
Year Founded2019
Last FundingOct 27, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?